Open AccessDabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Author(s) -
Sam Schulman,
Clive Kearon,
Ajay K. Kakkar,
Patrick Mismetti,
Sebastian Schellong,
Henry Eriksson,
David Baanstra,
Janet Schnee,
Samuel Z. Goldhaber
Publication year - 2009
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa0906598
Subject(s) - medicine , dabigatran , warfarin , interquartile range , hazard ratio , direct thrombin inhibitor , confidence interval , anesthesia , randomized controlled trial , adverse effect , surgery , atrial fibrillation
The direct oral thrombin inhibitor dabigatran has a predictable anticoagulant effect and may be an alternative therapy to warfarin for patients who have acute venous thromboembolism.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom